Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Macro,Photo,Of,Woman,With,Beautiful,Eyes,On,Grey,Background.

Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial.

The Spectra trial evaluates 4D-150 in patients with diabetic macular edema (DME). DME is a serious eye condition that can cause vision loss in people with diabetes.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.